சமூகம் க்கு இனப்பெருக்கம் விசாரணை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from சமூகம் க்கு இனப்பெருக்கம் விசாரணை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In சமூகம் க்கு இனப்பெருக்கம் விசாரணை Today - Breaking & Trending Today

ObsEva to Present Ebopiprant (OBE022) Data at the Society


ObsEva is developing ebopiprant, a potential first-in-class, once daily, oral and selective prostaglandin F
2α receptor antagonist, which is designed to control preterm labor by reducing inflammation, decreasing uterine contractions, preventing cervical changes and fetal membrane rupture without causing the potentially serious side effects to the fetus seen with non-specific prostaglandin synthesis inhibitors (NSAIDs). PGF
2α is believed to induce contractions of the myometrium and also upregulate enzymes causing cervix dilation and membrane rupture. In nonclinical studies, ObsEva has observed that ebopiprant markedly reduces spontaneous and induced uterine contractions in pregnant rats without causing the fetal side effects seen with non-specific prostaglandin inhibitors such as indomethacin. Ebopiprant (OBE022) was licensed from Merck KGaA, Darmstadt, Germany, in 2015. ObsEva retains worldwide, exclusive, commercial rights. ....

United States , Shauna Dillon , Joyce Allaire , Exchange Commission , Merck Kga , Industry Development In Preterm Labor Treatment , Society For Reproductive Investigation , Merck Kgaa , Swiss Exchange , Reproductive Investigation , Annual Meeting , Boston July , Proof Of Concept Trial , Spontaneous Preterm Labor , Elizabeth Garner , Chief Medical Officer , Pharmaceutical Industry Development , Preterm Labor Treatment , Nasdaq Global Select Market , Private Securities Litigation Reform Act , Risk Factors , Annual Report , ஒன்றுபட்டது மாநிலங்களில் , ஷ்ௌுனா டில்லன் , மகிழ்ச்சி அல்லேர் , பரிமாற்றம் தரகு ,

ObsEva SA: ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting


ObsEva SA: ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting
ePoster
,
2021 - ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women s reproductive health, today announced the presentation of clinical data from the PROLONG Phase 2a proof-of-concept study of ebopiprant, an oral prostaglandin F2alpha (PGF
2
a) antagonist, for the treatment of spontaneous preterm labor at the Society for Reproductive Investigation (SRI) 68
th Annual Meeting, being held virtually and in Boston July 6 -9, 2021.
Presentation details
are as follows:
Abstract ID: W-063
Session
Session Time: 4:00-5:30 p.m. ET ....

Shauna Dillon , Joyce Allaire , Exchange Commission , Merck Kga , Industry Development In Preterm Labor Treatment , Society For Reproductive Investigation , Merck Kgaa , Swiss Exchange , Reproductive Investigation , Annual Meeting , Boston July , Proof Of Concept Trial , Spontaneous Preterm Labor , Elizabeth Garner , Chief Medical Officer , Pharmaceutical Industry Development , Preterm Labor Treatment , Nasdaq Global Select Market , Private Securities Litigation Reform Act , Risk Factors , Annual Report , ஷ்ௌுனா டில்லன் , மகிழ்ச்சி அல்லேர் , பரிமாற்றம் தரகு , மெர்க் க்க , சமூகம் க்கு இனப்பெருக்கம் விசாரணை ,

Shady Grove Fertility (SGF) Welcomes Reproductive Endocrinologist, Emily Barnard, D.O., to the Washington, D.C. and Towson Physician Teams


Skip to main content
Currently Reading
Shady Grove Fertility (SGF) Welcomes Reproductive Endocrinologist, Emily Barnard, D.O., to the Washington, D.C. and Towson Physician Teams
PRWeb
FacebookTwitterEmail
WASHINGTON (PRWEB) March 01, 2021
Shady Grove Fertility (SGF) is proud to announce that reproductive endocrinologist, Emily Barnard, D.O., has joined the practice and will begin seeing patients at SGF’s Washington, D.C. - K Street and Towson offices in April 2021. Dr. Barnard will provide a full range of state-of-the-art, in-house diagnostic and treatment options for female and male infertility, elective egg freezing, LGBTQ family building, and fertility preservation prior to cancer treatment. ....

United States , Eric Widra , Emily Barnard , American Society For Reproductive Medicine , National Infertility Association , Kansas City University Of Medicine , American Congress , Society For Reproductive Endocrinology , Society For Reproductive Investigation , Society Of Gynecologic Surgeons , Mayo International Health Program Scholarship , Grove Fertility , Welcomes Reproductive Endocrinologist , Towson Physician , Kansas City University , International Health Program Scholarship , Reproductive Investigation , Womens Hospital , Gynecologic Surgeons , Reproductive Endocrinology , American Society , Reproductive Medicine , National Infertility , Medical Officer , Shady Grove Fertility , K Street ,